Sinovac effective against serious COVID-19 - study

Friday, 24. September 2021 09:35

A study conducted by the Malaysian government found that only 0.011% of 7.2 million people vaccinated with the Sinovac shot required intensive care unit treatment for COVID-19, according to health officials.

Despite being higher than the 0.002% and 0.001% recorded for Pfizer and AstraZeneca recipients respectively, the result is encouraging for Sinovac which has come under fire due to infections among fully vaccinated healthcare workers in Indonesia and Thailand.

Kalaiarasu Peariasamy, a director of the Institute for Clinical Research that conducted the study, noted that demographic differences in recipients could have also affected results, with AstraZeneca recipients generally in the "mid-adulthood age" as opposed to more vulnerable recipients of Pfizer and Sinovac vaccines.

Related Links: AstraZeneca plcBioNTech SEPfizer Inc.
Breaking the News / IB